AICAR 10mg 100pcs Oral Steroids Tablets

Description

AICAR AMPK Activator Oral Exercise Mimetic Research

Compound Background

AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside) is a cell-permeable nucleoside analog that functions as a potent pharmacological activator of the AMP-activated protein kinase (AMPK) signaling pathway. This signaling molecule belongs to the imidazocarboxamide class. It mimics the cellular metabolic signals of acute physical exertion without requiring high-intensity activity. [AICAR activates the AMPK pathway]. This compound provides a specific research model for investigating the molecular triggers of mitochondrial biogenesis and insulin-independent glucose disposal.

Specification Sheet

• CAS Number: 2627-69-2
• Molecular Formula: C9H14N4O5
• Molecular Weight: 258.23 g/mol
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white to off-white crystalline powder

How It Works

The biochemical activity of AICAR is defined by its intracellular conversion into ZMP (AICAR monophosphate), an analog of adenosine monophosphate (AMP). At the molecular level, the molecule enters the cell and is phosphorylated by adenosine kinase. This defines the first semantic triple: [AICAR mimics adenosine monophosphate]. Following this, ZMP binds to the gamma-subunit of the AMPK heterotrimer, inducing an allosteric conformational shift that promotes the phosphorylation of the catalytic alpha-subunit. This establishes the second triple: [ZMP activates the AMPK enzyme]. Thirdly, this activation initiates a downstream signaling cascade that facilitates the translocation of GLUT4 to the cell membrane. This forms the third triple: [AMPK activation stimulates glucose uptake]. Quantitatively, AICAR demonstrates an EC50 of approximately 0.5 mM for AMPK activation in various cell lines, with a systemic half-life of approximately 2.5 hours in research models. Unlike GW-501516 (Cardarine), which activates the PPAR-delta receptor to modulate lipid metabolism, AICAR directly engages the energy-sensing kinase of the cell to simulate a low-energy state.

Reported Findings

• Enhanced Endurance Enhancement: Users in research models commonly report significant increases in aerobic running distance and physical capacity through optimized oxygen utilization.
• Optimized Glucose Disposal: Published research indicates improved metabolic resilience and stabilized postprandial glucose levels without the need for insulin stimulation.
• Accelerated Lipid Oxidation: Based on community feedback, research models show a marked reduction in visceral fat accumulation by shifting the metabolic priority toward fatty acid catabolism.
• Mitochondrial Biogenesis Support: Aggregated data shows an increase in mitochondrial density within skeletal myocytes, facilitating more efficient ATP production.
• Preservation of Lean Muscle: Research models have observed the maintenance of muscle architecture during periods of forced inactivity or caloric deficits.

Summary:
AICAR Oral represents a premier research tool for investigating the direct enzymatic control of metabolism and the molecular triggers of mitochondrial biogenesis.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.